At a median follow-up of 16.3 months, 45 patients in the bortezomib group and 76 in the control group had died (hazard ratio in the bortezomib group, 0.61; P = 0.008), indicating

In this phase 3 trial, we randomly assigned 706 patients with newly diagnosed mul- tiple myeloma who were ineligible for stem-cell transplantation to receive nine cycles of

Thirty patients with re- lapsed or refractory MM were enrolled; 20 patients (67%) achieved a partial re- sponse (PR) including 13 patients (43%) who achieved at least a very good

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and

Based on the results of the Velcade as Initial Standard Therapy in Multiple Myeloma (VISTA) study, which showed a significant difference between bortezomib plus melphalan

Bortezomib, melphalan, and prednisone versus bort- ezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide

Carfilzomib plus melphalan and prednisone (CMP) is a promising combination therapy for the treatment of elderly patients with newly diagnosed multiple myeloma: results of a phase

Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. Phase 3 study (CLARION) of car filzomib,

TNT was similar between patients with high-risk versus standard-risk cytogenetics (median 24.1 v 27.4 months; HR, 1.478; P ⫽.17);survivalfromstartof subsequent therapy appeared

A Prospective, Multicenter, Randomized, Trial of bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide Prednisone (VTP) as Induction Therapy Followed

Our findings show that the oral combination of melphalan, prednisone, and thalidomide is more effective than standard treatment for newly diagnosed multiple myeloma.. This advantage

The role of bortezomib in combination with MP was examined in the large Phase III VISTA (VELCADE as Initial Standard Therapy in multiple myeloma: Assessment with melphalan

This final analysis of the phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone) was conducted to determine

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. Waage A, Gimsing P,

The addition of daratumumab to the standard combination treatment of bortezomib, melphalan and prednisone in untreated MM patients resulted in a

Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AI, de Paz R et al (2010) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as